LT2498799T - Fgfr1 ekstraląstelinio domeno baltymų panaudojimas gydymui vėžio su nuo ligando priklausančiomis, aktyvuojančiomis fgfr2 mutacijomis - Google Patents

Fgfr1 ekstraląstelinio domeno baltymų panaudojimas gydymui vėžio su nuo ligando priklausančiomis, aktyvuojančiomis fgfr2 mutacijomis

Info

Publication number
LT2498799T
LT2498799T LTEP10830834.7T LT10830834T LT2498799T LT 2498799 T LT2498799 T LT 2498799T LT 10830834 T LT10830834 T LT 10830834T LT 2498799 T LT2498799 T LT 2498799T
Authority
LT
Lithuania
Prior art keywords
fgfr2
fgfr1
ligand
activating mutations
domain proteins
Prior art date
Application number
LTEP10830834.7T
Other languages
English (en)
Inventor
Thomas Harding
Michael W. Kavanaugh
Original Assignee
Five Prime Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Five Prime Therapeutics, Inc. filed Critical Five Prime Therapeutics, Inc.
Publication of LT2498799T publication Critical patent/LT2498799T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LTEP10830834.7T 2009-11-13 2010-11-12 Fgfr1 ekstraląstelinio domeno baltymų panaudojimas gydymui vėžio su nuo ligando priklausančiomis, aktyvuojančiomis fgfr2 mutacijomis LT2498799T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26129109P 2009-11-13 2009-11-13
PCT/US2010/056627 WO2011060333A1 (en) 2009-11-13 2010-11-12 Use of fgfr1 extra cellular domain proteins to treat cancers characterized by ligand-dependent activating mutations in fgfr2

Publications (1)

Publication Number Publication Date
LT2498799T true LT2498799T (lt) 2016-11-10

Family

ID=43992083

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP10830834.7T LT2498799T (lt) 2009-11-13 2010-11-12 Fgfr1 ekstraląstelinio domeno baltymų panaudojimas gydymui vėžio su nuo ligando priklausančiomis, aktyvuojančiomis fgfr2 mutacijomis

Country Status (11)

Country Link
US (2) US8614183B2 (lt)
EP (1) EP2498799B1 (lt)
AU (1) AU2010319327B2 (lt)
CA (1) CA2780457A1 (lt)
CY (1) CY1119774T1 (lt)
DK (1) DK2498799T3 (lt)
ES (1) ES2600631T3 (lt)
LT (1) LT2498799T (lt)
PL (1) PL2498799T3 (lt)
PT (1) PT2498799T (lt)
WO (1) WO2011060333A1 (lt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ565511A (en) 2005-07-22 2011-03-31 Five Prime Therapeutics Inc Compositions and methods of treating disease with FGFR fusion proteins
WO2010017198A2 (en) 2008-08-04 2010-02-11 Five Prime Therapeutics, Inc. Fgfr extracellular domain acidic region muteins
US8445445B2 (en) 2009-09-15 2013-05-21 Five Prime Therapeutics, Inc. Method of promoting hair growth using FGFR4 extracellular domains
DK2498799T3 (en) 2009-11-13 2016-12-05 Five Prime Therapeutics Inc Use of the FGFR1 ECD proteins for the treatment of cancer diseases characterized by ligand dependent activating mutations in FGFR2
EP2512501A4 (en) 2009-12-17 2014-01-01 Five Prime Therapeutics Inc METHODS FOR PROMOTING HAIR GROWTH USING FGFR3 EXTRACELLULAR DOMAINS
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
SG190788A1 (en) * 2010-11-15 2013-07-31 Five Prime Therapeutics Inc Fgfr1 extracellular domain combination therapies
AU2015249133C1 (en) * 2010-11-15 2017-08-17 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble fgfr1 fusion proteins
US8951972B2 (en) 2010-12-09 2015-02-10 Five Prime Therapeutics, Inc. FGFR1 extracellular domain combination therapies for lung cancer
CN102219860B (zh) * 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 FGFR-Fc融合蛋白及其用途
US10400029B2 (en) 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
IL312872A (en) 2011-06-28 2024-07-01 Inhibrx Inc Methods for purifying fusion proteins containing serphin
US10016484B2 (en) 2011-11-14 2018-07-10 Five Prime Therapeutics, Inc. Methods of treating lung cancer
KR20160002681A (ko) 2013-01-16 2016-01-08 인썸(인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰메디칼르) 골격 성장 지연 질환의 예방 또는 치료에 사용하기 위한 용해성 섬유아세포 성장 인자 수용체 3(fgr3) 폴리펩티드
KR20150123250A (ko) 2013-03-06 2015-11-03 제넨테크, 인크. 암 약물 내성의 치료 및 예방 방법
US9957313B2 (en) 2013-03-15 2018-05-01 Remegen, Ltd. FGFR-FC fusion proteins and the use thereof
CN103757026B (zh) * 2013-12-20 2017-04-05 广州圣露生物技术有限公司 FGFR2b胞外段的基因序列、多肽及其应用
US20230190750A1 (en) 2014-06-13 2023-06-22 Genentech, Inc. Methods of treating and preventing cancer drug resistance
MX2018016257A (es) 2016-07-07 2019-11-21 Therachon Sas Polipéptidos del receptor 3 del factor de crecimiento de fibroblastos solubles (sfgfr3) y usos de los mismos.
TW202128173A (zh) * 2019-10-09 2021-08-01 美商G1治療公司 失調之纖維母細胞生長因子受體訊息傳遞的癌症之標靶性治療

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486462A (en) 1984-11-23 1996-01-23 The Regents Of The University Of California Differentiative expression modules
US5288855A (en) 1989-01-23 1994-02-22 Farmitalia Carlo Erba Extracellular form of the human fibroblast growth factor receptor
GB9001466D0 (en) 1990-01-23 1990-03-21 Erba Carlo Spa Extracellular form of the human fibroblast growth factor receptor
DK0481000T3 (da) 1989-07-06 1999-11-15 Univ California Receptorer for fibroblastvækstfaktorer
US5750371A (en) 1990-04-27 1998-05-12 Takeda Chemical Industries Ltd Water-soluble mutein of FGF receptor, DNA and production thereof
ES2204886T3 (es) 1990-07-06 2004-05-01 Gencell S.A. Receptores de factor de crecimiento fibroblastico.
US5863888A (en) 1990-07-06 1999-01-26 Rhone-Poulenc Rorer Pharmaceuticals Inc. Human Bek Fibroblast growth factor receptor
US5229501A (en) 1991-01-11 1993-07-20 Chiron Corporation Expression and use of human fibroblast growth factor receptor
IL100219A0 (en) 1991-12-02 1992-09-06 Yeda Res & Dev Variable region within fibroblast growth factor receptors that confers ligand specificity
US5474914A (en) 1992-07-29 1995-12-12 Chiron Corporation Method of producing secreted CMV glycoprotein H
US6517872B1 (en) 1995-06-12 2003-02-11 Yeda Research And Development Co., Ltd. FGFR3 as a marker for mesenchymal skeletal progenitor cells
US6323316B1 (en) 1996-06-18 2001-11-27 The United States Of America As Represented By The Secretary Of The Department Of And Human Services Fibroblast growth factor receptor activating gene 1 and related compositions and methods
DE19802377A1 (de) 1998-01-22 1999-08-19 Max Planck Gesellschaft Verwendung von Inhibitoren für die Behandlung von RTK-Überfunktions-bedingten Störungen, insbesondere von Krebs
AU3224700A (en) 1999-02-08 2000-08-25 Chiron Corporation Fibroblast growth factor receptor-immunoglobulin fusion
US7135311B1 (en) 1999-05-05 2006-11-14 Institut Curie Means for detecting and treating pathologies linked to FGFR3
ATE542545T1 (de) 2001-05-24 2012-02-15 Zymogenetics Inc Taci-immunoglobulin-fusionsproteine
WO2003038054A2 (en) 2001-10-31 2003-05-08 New York University Structure-based design and synthesis of fgf inhibitors and fgf modulator compounds
PT1543106E (pt) 2002-07-15 2007-05-31 Immunex Corp Métodos e meios para controlar a sialilação de proteínas produzidas por células de mamíferos
IL156495A0 (en) 2003-06-17 2004-01-04 Prochon Biotech Ltd Use of fgfr3 antagonists for treating t cell mediated diseases
WO2005066211A2 (en) 2003-12-19 2005-07-21 Five Prime Therapeutics, Inc. Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention
CA2565974A1 (en) 2004-05-14 2005-12-01 Receptor Biologix, Inc. Cell surface receptor isoforms and methods of identifying and using the same
WO2005115363A2 (en) 2004-05-25 2005-12-08 Yale University Method for treating skeletal disorders resulting from fgfr malfunction
CA2589895A1 (en) 2005-01-27 2006-08-03 Five Prime Therapeutics, Inc. Leader sequences for directing secretion of polypeptides and methods for production thereof
US20060234347A1 (en) 2005-04-13 2006-10-19 Harding Thomas C Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors
NZ565511A (en) 2005-07-22 2011-03-31 Five Prime Therapeutics Inc Compositions and methods of treating disease with FGFR fusion proteins
WO2007059574A1 (en) 2005-11-23 2007-05-31 Apollo Life Sciences Limited A molecule and chimeric molecules thereof
EP1989230B1 (en) 2006-02-10 2016-06-01 Genentech, Inc. Anti-fgf19 antibodies and methods using same
EP2018442A2 (en) 2006-05-12 2009-01-28 Genentech, Inc. Methods and compositions for the diagnosis and treatment of cancer
CL2007003411A1 (es) 2006-11-28 2008-07-04 Centelion Proteina fusion que consiste en una region fc de una inmunoglobulina con un fragmento o dominio soluble de un receptor para fgf; polinucleotido que la codifica y vector y celula que lo comprenden; composicion farmaceutica que comprende la proteina fu
EP2132331B1 (en) * 2007-03-23 2016-08-03 The Translational Genomics Research Institute Method of classifying endometrial cancer
WO2008133873A2 (en) 2007-04-25 2008-11-06 Aveo Pharmaceuticals, Inc. Fgf-binding fusion proteins
WO2010017198A2 (en) 2008-08-04 2010-02-11 Five Prime Therapeutics, Inc. Fgfr extracellular domain acidic region muteins
US8445445B2 (en) 2009-09-15 2013-05-21 Five Prime Therapeutics, Inc. Method of promoting hair growth using FGFR4 extracellular domains
DK2498799T3 (en) 2009-11-13 2016-12-05 Five Prime Therapeutics Inc Use of the FGFR1 ECD proteins for the treatment of cancer diseases characterized by ligand dependent activating mutations in FGFR2
EP2512501A4 (en) 2009-12-17 2014-01-01 Five Prime Therapeutics Inc METHODS FOR PROMOTING HAIR GROWTH USING FGFR3 EXTRACELLULAR DOMAINS
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
US8951972B2 (en) 2010-12-09 2015-02-10 Five Prime Therapeutics, Inc. FGFR1 extracellular domain combination therapies for lung cancer
KR20140012137A (ko) 2011-03-17 2014-01-29 노파르티스 아게 Hr 양성 대상체에서의 유방암용 바이오마커로서의 fgfr 및 이의 리간드
WO2012177481A2 (en) 2011-06-24 2012-12-27 University Of Miami Fibroblast growth factor receptor inhibition for the treatment of disease
US10016484B2 (en) 2011-11-14 2018-07-10 Five Prime Therapeutics, Inc. Methods of treating lung cancer

Also Published As

Publication number Publication date
EP2498799A1 (en) 2012-09-19
AU2010319327B2 (en) 2015-08-13
AU2010319327A1 (en) 2012-05-31
CY1119774T1 (el) 2018-06-27
DK2498799T3 (en) 2016-12-05
EP2498799B1 (en) 2016-08-17
ES2600631T3 (es) 2017-02-10
US20140227263A1 (en) 2014-08-14
CA2780457A1 (en) 2011-05-19
US20120251538A1 (en) 2012-10-04
WO2011060333A1 (en) 2011-05-19
US9169313B2 (en) 2015-10-27
PT2498799T (pt) 2016-11-04
US8614183B2 (en) 2013-12-24
PL2498799T3 (pl) 2017-03-31
EP2498799A4 (en) 2013-12-18

Similar Documents

Publication Publication Date Title
PL2498799T3 (pl) Zastosowanie białek domeny zewnątrzkomórkowej FGFR1 do leczenia nowotworów charakteryzujących się mutacjami aktywującymi zależnymi od ligandów w FGFR2
HK1244496A1 (zh) 抗體muc16及其使用方法
IL228740A0 (en) fgfri agonists and methods of use
EP2504031A4 (en) ANTI-IL-6 ANTIBODIES AND THEIR USE
GB201213868D0 (en) Improvements in or relating to methods of manufacture
IL207794A0 (en) Communication in context of content
EP2632490A4 (en) NOVEL MOLECULES BINDING TO THE EGF RECEPTOR AND IMMUNOCONJUGATES THEREOF
HK1155184A1 (en) Antibodies to il-6 and their uses il-6
IL218934A0 (en) Novel heterocyclic acrylamides and their use as phermaceuticals
EP2488891A4 (en) CARDS WITH SHORT AND ULTRA SHORT BASIC LINE PHASE
UY33079A (es) Derivados de difenil -pirazolopiridinas, su preparación y su aplicación en terapeutica
EP2502939A4 (en) NON-NATURAL PROTEIN OF THE COLLAGEN TYPE AND USE THEREOF
EP2880079A4 (en) SYNTHESIS OF PHTHALONITRILES AND CURING ADDITIVES FOR PHTHALONITRILES
GB0801479D0 (en) Improvements to methods of in field analysis
ZA201303501B (en) Treatment of cancer with elevated dosages of soluble fgfr1 fusion proteins
GB201015360D0 (en) Improvements in relation to table
GB0902537D0 (en) Improvememts in or relating to the creation of curved forms
GB2475483B (en) Improvements in relation to mesh-sided trailers
EP2436694A4 (en) NEW GPCR PROTEIN AND ITS USE
EP2591368A4 (en) METHOD FOR DETERMINING ETHANOL CONSUMPTION
GB201006478D0 (en) Improvements in or relatigng to automobile components
GB0902538D0 (en) Improvvements in or relating to the creation of curved forms
EP2533794A4 (en) PROTEIN DOMAINS AND ASSOCIATED USES
GB201014325D0 (en) Improvements in and relating to toilet sanitation
HU1000252D0 (en) Formation of water crystal in human body